摘要
Abstract
Objective To investigate the curative effect of radiotherapy combined with epidermal growth factor receptor mutation-tyrosine kinase inhibitor (EGFR-TKI) targeted therapy for stage Ⅳ non-small cell lung cancer (NSCLC) and its influence on internal environment in patients.Methods 53 stage Ⅳ NSCLC patients with EGFR mutation admitted to oncology department of our hospital from March 2014 to December 2017 were selected retrospectively.According to the treatment plan,they were divided into two groups.The control group (n=26) was treated with systemic chemotherapy combined with radiotherapy,and the observation group (n=27)was treated with radiotherapy combined with EGFR-TKI targeted therapy.The clinical efficacy,immune function,and toxic and side effects of the two groups were observed.Results In terms of clinical efficacy,the objective response rate (ORR) of the observation group was 74.07％,which was significantly higher than 38.46％ of the control group (P＜0.05).In terms of immune function,CD8+ in the observation group decreased significantly after treatment (P＜0.05),and CD4+/CD8+ increased significantly after treatment (P＜0.05),but there were no significant changes in CD8+,CD4+/CD8+ in the control group after treatment (P＞0.05);CD8+ in the observation group was significantly lower than that in the control group after treatment (P＜0.05),while CD4+/CD8+ was significantly higher than that in the control group (P＜0.05).In terms of toxicity and side effects,which occurred in both groups,but no more than grade Ⅱ reactions were found,and there was no statistically significant difference in the incidence of toxicity and side effects between the two groups (P＞0.05).Conclusion Radiotherapy combined with EGFR-TKI targeted therapy for stage Ⅳ NSCLC patients can significantly improve the clinical objective efficiency,improve the patients' internal environment,and improve the immune capacity of the body.However,many factors should be taken into account in the clinical treatment of stage Ⅳ NSCLC patients.关键词
非小细胞肺癌/靶向治疗/EGFR-TKI/毒副作用Key words
Non-small cell lung cancer (NSCLC)/Targeted therapy/Epidermal growth factor receptor mutation-tyrosine kinase inhibitor (EGFR-TKI)/Toxicity and side effects
